Researchers found that inhibiting GSK-3 led to less defects in the axonal transport process and less neuronal cell death, while inhibiting ERK1 led to more transport problems and more cell death.

Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

Glycogen synthase kinase 3 (GSK3) was initially described as a key enzyme involved in glycogen metabolism, but is now known to regulate a diverse array of cell functions. The study of the ...

Actuate Therapeutics, Inc. announced that data on their investigational drug elraglusib, designed to treat advanced salivary gland carcinoma by inhibiting glycogen synthase kinase-3 beta (GSK-3β ...